Provider Briefing: Ebglyss Access and Availability in 2026

Since its FDA approval in September 2024, Ebglyss (Lebrikizumab-lbkz) has emerged as a valuable addition to the biologic armamentarium for moderate-to-severe atopic dermatitis. However, prescribers across dermatology and allergy practices are encountering consistent challenges around patient access and drug availability.

This article provides a clinical and operational overview of the current Ebglyss landscape — including distribution status, insurance dynamics, and practical tools — to help you support your patients more effectively.

Timeline: Ebglyss's Path to Market

Understanding Ebglyss's regulatory history provides important context for its current market position:

• November 2023: Approved by the European Medicines Agency (EMA) for moderate-to-severe atopic dermatitis in adults
• September 2023: FDA issued a Complete Response Letter (CRL) due to manufacturing facility inspection findings — not related to clinical data, drug safety, or labeling
• June 2024: Approved in Canada
• September 2024: FDA approval granted for adults and adolescents (≥12 years, ≥40 kg) with moderate-to-severe atopic dermatitis inadequately controlled by topical therapies or when such therapies are inadvisable

The one-year delay between the initial CRL and final approval meant Eli Lilly had a compressed timeline to build U.S. specialty pharmacy distribution networks — contributing to the access gaps providers and patients are experiencing now.

Prescribing Implications

Approved Population

Ebglyss is indicated for moderate-to-severe atopic dermatitis in patients ≥12 years of age weighing ≥40 kg who are candidates for systemic therapy. Approval was based on three Phase 3 trials (ADvocate 1, ADvocate 2, ADhere) enrolling 1,062 subjects.

Dosing Overview

• Loading dose: 500 mg (two 250 mg subcutaneous injections) at Week 0 and Week 2
• Induction: 250 mg Q2W through Week 16
• Maintenance: 250 mg Q4W for responders (IGA 0/1 or EASI-75 at Week 16)
• Non-responders at Week 16: Continue 250 mg Q2W

Efficacy Benchmarks

In ADvocate 1 and ADvocate 2, approximately 33-38% of patients achieved IGA 0/1 at Week 16 (vs. 11-12% placebo), and 52-59% achieved EASI-75 (vs. 18-22% placebo). Maintenance data through Week 52 demonstrated durability of response on both Q2W and Q4W dosing schedules.

Safety Profile

The safety profile is consistent with the IL-13 inhibitor class:

• Injection site reactions (most common)
• Conjunctivitis and allergic conjunctivitis (notable class effect — counsel patients proactively)
• No boxed warning
• No routine laboratory monitoring required
• Avoid concomitant live vaccines

For detailed side effect information, refer patients to Ebglyss side effects: what to expect.

Current Availability Picture

As of early 2026:

• No active shortage on FDA or ASHP drug shortage databases
• Ebglyss is distributed exclusively through specialty pharmacy channels — it is not available at standard retail pharmacies
• Distribution is still expanding, with availability varying by region and specialty pharmacy network
• Patients frequently report difficulty locating the drug, primarily due to specialty pharmacy routing rather than supply constraints

Key Distribution Partners

Major specialty pharmacy networks dispensing Ebglyss include Accredo, CVS Specialty, OptumRx Specialty, and AllianceRx Walgreens Specialty. Practices should confirm which networks are compatible with their patients' insurance plans.

Cost and Access Considerations

Pricing

• Wholesale acquisition cost (WAC): Approximately $2,500–$3,800 per 250 mg injection
• Monthly maintenance cost (Q4W): ~$3,200/month
• Annual cost: Approximately $38,000–$45,000 depending on dosing phase

Insurance Landscape

Most commercial payers and Medicare Part D plans cover Ebglyss but require:

• Prior authorization (nearly universal)
• Step therapy: Many plans require documented failure of topical therapies and often at least one biologic (typically Dupixent) before approving Ebglyss
• Specialty tier placement: Higher patient cost-sharing unless supplemented by manufacturer copay programs

Manufacturer Support Programs

• Ebglyss Savings Card: Eligible commercially insured patients may pay as little as $0 per injection (maximum annual benefit applies)
• Lilly Cares Foundation: Patient assistance program providing Ebglyss at no cost for qualifying uninsured or underinsured patients
• Enrollment: ebglyss.com or 1-800-545-6962

For patient-facing cost information, direct patients to how to save money on Ebglyss.

Tools and Resources for Your Practice

Medfinder for Providers

Medfinder for Providers enables real-time pharmacy availability searches, helping your practice staff quickly identify which specialty pharmacies near your patients have Ebglyss in stock. This can dramatically reduce the time your team spends on phone calls to locate the drug.

Streamlining the Prescribing Workflow

• E-prescribe directly to specialty pharmacies — avoid sending to retail pharmacies where the prescription will need to be transferred
• Initiate prior authorization at the time of prescribing — don't wait for the pharmacy to trigger the PA process
• Document previous treatment failures thoroughly — include specific agents, durations, and outcomes to strengthen PA submissions
• Enroll patients in manufacturer savings programs during the office visit — this prevents cost surprises that lead to abandonment

Therapeutic Alternatives

When Ebglyss isn't accessible or isn't covered, consider these alternatives:

• Dupixent (Dupilumab): IL-4/IL-13 inhibitor — broadest insurance coverage, longest real-world track record
• Adbry (Tralokinumab): IL-13 inhibitor — most similar mechanism; adults only
• Rinvoq (Upadacitinib): Oral JAK inhibitor — convenient dosing but carries boxed warning; ages 12+
• Cibinqo (Abrocitinib): Oral JAK inhibitor — adults only; boxed warning

For a patient-facing comparison, see alternatives to Ebglyss.

Looking Ahead

The atopic dermatitis biologic market is maturing rapidly. As Ebglyss's distribution networks expand throughout 2026, access should improve. However, prescribers should continue to anticipate insurance-related delays and proactively support patients through the specialty pharmacy onboarding process.

Eli Lilly has indicated continued investment in expanding specialty pharmacy partnerships and streamlining the prior authorization process. Providers who build strong relationships with their preferred specialty pharmacies and leverage tools like Medfinder for Providers will be best positioned to minimize disruptions for their patients.

Final Thoughts

Ebglyss represents a meaningful therapeutic advance for moderate-to-severe atopic dermatitis, offering targeted IL-13 inhibition with a favorable safety profile and a maintenance dosing schedule that patients appreciate. The current access challenges are primarily logistical — not supply-driven — and should continue to improve as the drug matures in the market.

In the meantime, proactive prescribing practices, early PA initiation, and patient education on specialty pharmacy processes can make a substantial difference in treatment continuity. Visit medfinder.com/providers for tools to support your workflow.